Status quo und Entwicklungen in der perioperativen Therapie des ösophagogastralen Adenokarzinoms

Zusammenfassung

Lokal fortgeschrittene Adenokarzinome des Ösophagus, des ösophagogastralen Übergangs und des Magens werden nach Maßgabe der Deutschen S3-Leitlinien in der Regel perioperativ behandelt. In den letzten Jahren haben sich viele Studien der Erforschung und Etablierung perioperativer Therapiekonzepte gewidmet. Nach wie vor werden beide Tumorentitäten jedoch weltweit in unterschiedlicher Weise behandelt. In Europa dominiert der präoperative, das heißt neoadjuvante Therapieansatz bei lokal fortgeschrittenen Tumoren. In der vorliegenden Arbeit werden die wichtigsten Studien zur perioperativen Therapie ösophagogastraler Adenokarzinome kurz referiert und ein Ausblick auf laufende Studien gegeben.

Summary

Locally advanced adenocarcinoma of the esophagus, the esophagogastric junction and the stomach are generally treated perioperatively according to the German S3 guidelines. During past years several clinical trials sought to improve perioperative treatment of these tumors. Nevertheless, perioperative treatment of these tumors still differs in several parts of the world. In Europe, preoperative, i. e. neoadjuvant treatment is preferred for locally advanced disease. The present review briefly describes recently published or ongoing pivotal trials on perioperative treatment for esophagogastric.

Schlüsselwörter

Adenokarzinom des Ösophagus - Magenkarzinom - perioperative Chemotherapie - neoadjuvante Radiochemotherapie

Keywords

Esophageal adenocarcinoma - gastric cancer - perioperative chemotherapy - neoadjuvant radiochemotherapy

• Literatur

• 1 Allum WH, Stenning SP, Bancewicz J et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27(30): 5062-7
• 2 Bajetta E. Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer. J Clin Oncol 2012; 30 (suppl; abstr LBA4001)
• 3 Bang YJ, Van Cutsem E, Feyereislova A et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376(9742): 687-97 Epub 2010 Aug 19
• 4 Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1): 11-20
• 5 Fuchs CS, Tepper JE, Niedzwiecki D et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 2011; 29 (suppl; abstr 4003)
• 6 Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8(3): 226-34
• 7 Homann N et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer 2012; 130(7): 1706-13 Epub 2011 Aug 5
• 8 Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002; 168(11): 597-608
• 9 Kim S, Lim DH, Lee J et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63(5): 1279-1285
• 10 Lee J, Lim DH, Kim S et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-273
• 11 Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345(10): 725-30
• 12 Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359(9319): 1727-33
• 13 Moehler M, Al-Batran SE, Andus T et al. German S3-guideline „Diagnosis and treatment of esophagogastric cancer“. Z Gastroenterol 2011; 49(4): 461-531
• 14 Paoletti X, Oba K, Burzykowski T et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303(17): 1729-1737
• 15 Schuhmacher C, Gretschel S, Lordick F et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28(35): 5210-8
• 16 Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27(6): 851-6
• 17 van Hagen P, Hulshof MC, van Lanschot JJ et al. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366(22): 2074-84
• 18 Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29(13): 1715-21